PTC Therapeutics Acquires ST-920 Fabry Disease Gene Therapy for $111M Upfront — PTC Therapeutics, Inc.

Event summary

PTC Therapeutics acquires ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a bankruptcy auction.
$111M upfront payment with up to $100M in contingent milestone payments based on regulatory approvals.
Rolling BLA submission expected to be completed in Q4 2026, with potential commercial launch in 2027.
ST-920 demonstrated positive mean annualized eGFR slope at 52 weeks and durable clinical benefits in the Phase 1/2 STAAR study.

The big picture

PTC Therapeutics' acquisition of ST-920 aligns with its strategy to expand its rare disease portfolio through leveraging existing commercial infrastructure. The deal underscores the growing trend of biopharmaceutical companies acquiring late-stage assets in competitive bankruptcy auctions to accelerate revenue growth. With a focus on Fabry disease, PTC aims to capitalize on the unmet medical needs of patients and the potential for significant returns on investment.

What we're watching

Regulatory Approval: Whether the FDA will grant accelerated approval for ST-920 based on the intermediate clinical endpoint of annualized eGFR at Week 52.
Commercial Launch: The pace at which PTC can commercialize ST-920 following potential approval, leveraging its existing rare disease infrastructure.
Financial Performance: How the acquisition and potential milestone payments will impact PTC's cash flow break-even objective for 2026.